95928-49-7

Basic information

• Product Name: 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester
• Synonyms: 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester;5-PyriMidinecarboxylic acid, 1,2-dihydro-2-oxo-, ethyl ester;PyriMidin-5-carboxylic acid 1,2-dihydro-2-oxo-, ethyl ester;2-Oxo-1,2-dihydro-pyrimidine-5-carboxylic acid ethyl ester;2-Hydroxy-pyrimidine-5-carboxylic acid ethyl ester
• CAS NO: 95928-49-7
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168
• Mol File: 95928-49-7.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1.33
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.18±0.10(Predicted)
• CAS DataBase Reference: 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester(95928-49-7)
• EPA Substance Registry System: 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester(95928-49-7)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 95928-49-7(Hazardous Substances Data)

Usage

General Description

1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester, also known as Ethyl 1,2-dihydro-2-oxopyrimidine-5-carboxylate, is a chemical compound with the molecular formula C8H10N2O4. 1,2-Dihydro-2-oxo-5-pyrimidinecarboxylic acid ethyl ester belongs to the class of organic compounds known as pyrimidinecarboxylic acids and derivatives, which are compounds containing a pyrimidine ring which bears a carboxylic acid group. No further information in regards to its uses, physical properties, or health effects could be found, implying that this compound might not have been sufficiently researched or that it doesn't have significant industrial or therapeutic relevance.

Upstream product

• 33458-27-4 ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 763-69-9 ethyl 3-ethoxypropionate 
• 34780-29-5 3-oxo-propionic acid ethyl ester 
• 879008-23-8 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 1086272-71-0 Ethyl (2E)-2-(ethoxymethyl)-3-methoxyacrylate 
• 2974-30-3 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 

Downstream Products

• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 110099-99-5 2-CHLOROPYRIMIDINE-5-CARBONYLCHLORIDE 
• 1213234-97-9 ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetate 
• 603965-77-1 ethyl 2-(piperazin-1-yl) pyrimidine-5-carboxylate 
• 1235450-27-7 Ethyl 2-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methylamino)pyrimidine-5-carboxylate 
• 1235450-94-8 methyl 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-97-1 methyl 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235451-07-6 ethyl 2-(((2-(4-aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235451-15-6 ethyl 2-(((2-chloro-4-(phenylamino)thieno[3,2-d]pyrimidine-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-95-9 ethyl 2-(((2-(4-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-96-0 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235450-98-2 ethyl 2-(((2-(3-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-99-3 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235451-08-7 ethyl 2-(((2-(4-acetamidophenyl)-4-morpholinothieno-[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 

Relevant articles and documents

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT